1. Home
  2. JAZZ vs ICLR Comparison

JAZZ vs ICLR Comparison

Compare JAZZ & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

N/A

Current Price

$242.66

Market Cap

16.1B

Sector

Health Care

ML Signal

N/A

Logo ICON plc

ICLR

ICON plc

N/A

Current Price

$193.77

Market Cap

13.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JAZZ
ICLR
Founded
2003
1990
Country
Ireland
Ireland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.1B
13.1B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
JAZZ
ICLR
Price
$242.66
$193.77
Analyst Decision
Buy
Buy
Analyst Count
22
18
Target Price
★ $297.50
$231.29
AVG Volume (30 Days)
691.1K
★ 1.1M
Earning Date
11-02-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.04
N/A
Revenue
★ $1,618,693,000.00
N/A
Revenue This Year
$12.68
N/A
Revenue Next Year
$5.34
$4.60
P/E Ratio
$6,014.25
★ $12.91
Revenue Growth
N/A
N/A
52 Week Low
$156.95
$66.57
52 Week High
$266.38
$219.04

Technical Indicators

Market Signals
Indicator
JAZZ
ICLR
Relative Strength Index (RSI) 61.11 51.53
Support Level $236.70 $157.92
Resistance Level $250.49 $219.04
Average True Range (ATR) 7.43 7.11
MACD 2.04 -2.33
Stochastic Oscillator 81.96 21.43

Price Performance

Historical Comparison
JAZZ
ICLR

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About ICLR ICON plc

Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.

Share on Social Networks: